Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Neonatal fc receptor blockers
6 evidence topics · 6 sources
Mechanism, onset, and comparative effect of FcRn blockers: Nordic guidance
“Monoclonal antibodies directed at the FcRn receptor's binding site for IgG block recycling and lead to a 60%–70% reduction in circulating IgG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The treatment can be tailored according to the disease state; new treatment cycles can be administered with signs of symptom worsening or according to a fixed schedule.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The number of treatment responders and the magnitude of the treatment response for FcRn blockers and complement inhibitors seem to be similar. No prospective and controlled head‐to‐head studies have been undertaken.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote